Home
Hepion Pharmaceuticals’ Product CRV431 Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.

Hepion Pharmaceuticals’ Product CRV431 Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.

Impacting News October 17, 2019

Hepion Pharmaceuticals
CRV431 Decreased Liver Fibrosis and Tumor Burden in Experimental Models
EDISON, NJ / ACCESSWIRE / October 16, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Impacting News
October 17, 2019

Other Articles